Patents by Inventor Marc Feary

Marc Feary has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11781116
    Abstract: A mammalian cell comprising at least four distinct recombination target sites (RTS), an adenovirus (Ad) gene comprising E1A, E1B or a combination thereof, and a promoter operatively linked to the Ad gene, wherein the RTS, the Ad gene, and the promoter are chromosomally-integrated; methods for using the cell for generating a recombinant adeno-associated virus (rAAV) producer host cell; and methods for using the AAV producer host cell to produce, package and purify rAAV.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: October 10, 2023
    Assignee: LONZA LTD.
    Inventors: Marc Feary, Robert J. Young, Anandita Seth
  • Patent number: 10669541
    Abstract: Methods for generating mammalian cells characterized by an increased concentration of at least one of miR-15, miR-16, and miR-34 for producing proteins at an industrial scale are provided. Methods for using the mammalian cells, in particular for the production of proteins of interest, are also provided.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: June 2, 2020
    Assignee: LONZA BIOLOGICS PLC.
    Inventors: Marc Feary, James Rance, Robert Young, Elizabeth C. Sayer, Christopher M. Smales
  • Publication number: 20200002727
    Abstract: The present disclosure relates to a site-specific integration (SSI) mammalian cell that comprises at least two distinct recombination target sites (RTS) wherein two RTS are chromosomally-integrated within the NL1 locus or the NL2 locus. The disclosure also relates to a SSI mammalian cell comprising at least four distinct RTS wherein two RTS are chromosomally-integrated within the NL1 or the NL2 locus and two RTS are chromosomally-integrated within a separate locus. The disclosure also relates to methods for using the SSI mammalian cell to produce recombinant protein expression cell lines that can express difficult to express proteins.
    Type: Application
    Filed: February 17, 2018
    Publication date: January 2, 2020
    Inventors: Marc FEARY, Robert J. YOUNG, Mark MOFFAT, Gerald Fries CASPERSON, Heather Laurence JONES, Lin ZHANG
  • Publication number: 20200002682
    Abstract: A mammalian cell comprising at least four distinct recombination target sites (RTS), an adenovirus (Ad) gene comprising E1A, E1B or a combination thereof, and a promoter operatively linked to the Ad gene, wherein the RTS, the Ad gene, and the promoter are chromosomally-integrated; methods for using the cell for generating a recombinant adeno-associated virus (rAAV) producer host cell; and methods for using the AAV producer host cell to produce, package and purify rAAV.
    Type: Application
    Filed: February 17, 2018
    Publication date: January 2, 2020
    Inventors: Marc FEARY, Robert J. YOUNG, Anandita SETH
  • Publication number: 20200002721
    Abstract: The present invention relates to expression vectors for the heterologous expression of a nucleic acid sequence of interest in mammalian cells, the vectors comprising a chimeric promoter regulatory sequence being operably linked to a nucleic acid sequence to be expressed, wherein the chimeric promoter regulatory sequence comprises a cytomegalovirus promoter sequence derived from murine cytomegalovirus or from human cytomegalovirus and being operably linked to the transcriptional start site of the nucleic acid sequence to be expressed; and a cytomegalovirus upstream region and/or enhancer sequence derived from human and/or the simian cytomegalovirus, wherein the upstream region and/or enhancer sequence is located 5? of and operably linked to the murine or the human promoter sequence, and wherein the chimeric promoter regulatory sequence comprises sequence elements being derived from at least two of the group consisting of murine cytomegalovirus, human cytomegalovirus and simian cytomegalovirus.
    Type: Application
    Filed: April 2, 2019
    Publication date: January 2, 2020
    Inventors: Tom Payne, Robert Young, Marc Feary
  • Patent number: 10294491
    Abstract: The present invention relates to expression vectors for the heterologous expression of a nucleic acid sequence of interest in mammalian cells, the vectors comprising a chimeric promoter regulatory sequence being operably linked to a nucleic acid sequence to be expressed, wherein the chimeric promoter regulatory sequence comprises a cytomegalovirus promoter sequence derived from murine cytomegalovirus or from human cytomegalovirus and being operably linked to the transcriptional start site of the nucleic acid sequence to be expressed; and a cytomegalovirus upstream region and/or enhancer sequence derived from human and/or the simian cytomegalovirus, wherein the upstream region and/or enhancer sequence is located 5? of and operably linked to the murine or the human promoter sequence, and wherein the chimeric promoter regulatory sequence comprises sequence elements being derived from at least two of the group consisting of murine cytomegalovirus, human cytomegalovirus and simian cytomegalovirus.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: May 21, 2019
    Assignee: LONZA BIOLOGICS PLC.
    Inventors: Tom Payne, Robert Young, Marc Feary
  • Publication number: 20170356007
    Abstract: The present invention relates to expression vectors for the heterologous expression of a nucleic acid sequence of interest in mammalian cells, the vectors comprising a chimeric promoter regulatory sequence being operably linked to a nucleic acid sequence to be expressed, wherein the chimeric promoter regulatory sequence comprises a cytomegalovirus promoter sequence derived from murine cytomegalovirus or from human cytomegalovirus and being operably linked to the transcriptional start site of the nucleic acid sequence to be expressed; and a cytomegalovirus upstream region and/or enhancer sequence derived from human and/or the simian cytomegalovirus, wherein the upstream region and/or enhancer sequence is located 5? of and operably linked to the murine or the human promoter sequence, and wherein the chimeric promoter regulatory sequence comprises sequence elements being derived from at least two of the group consisting of murine cytomegalovirus, human cytomegalovirus and simian cytomegalovirus.
    Type: Application
    Filed: August 28, 2017
    Publication date: December 14, 2017
    Inventors: Tom Payne, Robert Young, Marc Feary
  • Patent number: 9777290
    Abstract: The present invention relates to expression vectors for the heterologous expression of a nucleic acid sequence of interest in mammalian cells, the vectors comprising a chimeric promoter regulatory sequence being operably linked to a nucleic acid sequence to be expressed, wherein the chimeric promoter regulatory sequence comprises a cytomegalovirus promoter sequence derived from murine cytomegalovirus or from human cytomegalovirus and being operably linked to the transcriptional start site of the nucleic acid sequence to be expressed; and a cytomegalovirus upstream region and/or enhancer sequence derived from human and/or the simian cytomegalovirus, wherein the upstream region and/or enhancer sequence is located 5? of and operably linked to the murine or the human promoter sequence, and wherein the chimeric promoter regulatory sequence comprises sequence elements being derived from at least two of the group consisting of murine cytomegalovirus, human cytomegalovirus and simian cytomegalovirus.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: October 3, 2017
    Assignee: Lonza Biologics Plc
    Inventors: Tom Payne, Robert Young, Marc Feary
  • Publication number: 20160177300
    Abstract: The present invention relates to the generation of mammalian cells capable of producing proteins at an industrial scale and means and methods to obtain and use said cells, in particular for protein production.
    Type: Application
    Filed: July 30, 2014
    Publication date: June 23, 2016
    Applicant: LONZA BIOLOGICS PLC
    Inventors: Marc FEARY, James RANCE, Robert YOUNG, Elizabeth C. SAYER, Christopher M. SMALES
  • Publication number: 20150218584
    Abstract: The present invention relates to expression vectors for the heterologous expression of a nucleic acid sequence of interest in mammalian cells, the vectors comprising a chimeric promoter regulatory sequence being operably linked to a nucleic acid sequence to be expressed, wherein the chimeric promoter regulatory sequence comprises a cytomegalovirus promoter sequence derived from murine cytomegalovirus or from human cytomegalovirus and being operably linked to the transcriptional start site of the nucleic acid sequence to be expressed; and a cytomegalovirus upstream region and/or enhancer sequence derived from human and/or the simian cytomegalovirus, wherein the upstream region and/or enhancer sequence is located 5? of and operably linked to the murine or the human promoter sequence, and wherein the chimeric promoter regulatory sequence comprises sequence elements being derived from at least two of the group consisting of murine cytomegalovirus, human cytomegalovirus and simian cytomegalovirus.
    Type: Application
    Filed: September 23, 2013
    Publication date: August 6, 2015
    Inventors: Tom Payne, Robert Young, Marc Feary